NYT goes to town on drug factory failings

By Nick Taylor

The New York Times has run a big feature on failings at pharmaceutical manufacturing plants. Problems at Hospira ($HSP), Ben Venue and other sterile injectable plants are dragged up as the NYT shows that it's not just compounding pharmacies that have quality issues. "In the industry, everyone knows that all of the factories are in terrible shape," an academic said. Article

Suggested Articles

Lonza CEO Marc Funk is leaving for "personal reasons" after less than a year in the top job. 

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.